Table 2.
Prevalence of AMD features by age category (eye-level analysis, unweighted)
| Colour/en face grading | Multimodal grading (Infra-red and OCT) | ||||||||||||
| Age (years) |
Number at risk | Hyperpigmentation | Drusen (any size) |
Drusen ≥63 µm | Drusen ≥125 µm | Reticular Drusen | GA | Number at risk | Drusen (any size) |
SDD | cRORA | CNV | Vitelliform |
| All ≥55 | 5128 | 2.0 (1.5, 2.4) | 28.9 (27.4 to 30.4) | 14.5 (13.4 to 15.7) | 3.9 (3.3 to 4.5) | 3.2 (2.7 to 3.9) | 0.3 (0.2 to 0.6) | 5450 | 27.5 (26.1 to 29.0) | 25.7 (24.3 to 27.1) | 4.3 (3.7 to 5.0) | 0.3 (0.2 to 0.5) | 0.3 (0.2, 0.6) |
| <55 | 1131 | 1.0 (0.5, 1.7) | 26.0 (23.0 to 29.2) | 7.9 (6.1 to 9.9) | 1.3 (0.7 to 2.4) | 1.3 (0.6 to 2.5) | 0.0 | 1151 | 16.3 (13.9 to 19.0) | 13.0 (10.9 to 15.4) | 2.5 (1.5 to 3.9) | 0.0 | 0.0 |
| 55–64 | 2447 | 1.0 (0.6, 1.6) | 24.7 (22.7 to 26.8) | 10.2 (8.8 to 11.6) | 1.9 (1.4 to 2.6) | 1.1 (0.7 to 1.7) | 0.0 | 2534 | 20.4 (18.5 to 22.3) | 18.3 (16.6 to 20.1) | 2.9 (2.2 to 3.7) | 0.0 (0.0 to 0.2) | 0.0 (0.0, 0.2) |
| 65–74 | 2003 | 2.4 (1.7, 3.3) | 30.6 (28.2 to 33.1) | 16.4 (14.5 to 18.5) | 4.7 (3.6 to 6.0) | 3.8 (2.8 to 5.1) | 0.5 (0.2 to 1.1) | 2144 | 29.5 (27.1 to 31.9) | 27.3 (25.1 to 29.6) | 4.7 (3.7 to 5.8) | 0.2 (0.1 to 0.7) | 0.6 (0.2, 1.1) |
| 75–84 | 595 | 3.2 (1.8, 5.2) | 38.8 (33.9 to 43.9) | 24.7 (20.5 to 29.4) | 8.2 (5.7 to 11.4) | 8.6 (5.9 to 11.9) | 1.2 (0.4 to 2.6) | 675 | 44.3 (39.5 to 49.2) | 44.1 (39.5 to 48.9) | 6.8 (4.7 to 9.5) | 0.8 (0.3 to 1.9) | 0.6 (0.1, 2.1) |
| ≥85 | 83 | 9.6 (3.4, 20.5) | 39.8 (26.8 to 53.9) | 22.9 (12.1 to 37.1) | 9.6 (3.4 to 20.5) | 12.0 (4.0 to 26.0) | 0.0 | 97 | 54.6 (40.9 to 67.9) | 53.6 (40.1 to 66.8) | 16.5 (8.2 to 28.2) | 6.0 (2.0 to 13.5) | 2.1 (0.0, 11.1) |
Table 2 shows the prevalence of AMD features on en face and multimodal grading (non-weighted) (eye level). The all category is restricted to those over 55 years to enable comparison with other studies who restrict definition of AMD to this age category.
AMD, age-related macular degeneration; CNV, choroidal neovascular membrane; cRORA, complete retinal pigment epithelium and outer retinal atrophy; GA, geographic atrophy; OCT, optical coherence tomography; SDD, subretinal drusenoid deposit.